35015-91-9

Basic information

• Product Name: 3-AMINO-QUINOXALINE-2-OL
• Synonyms: 3-AMINO-QUINOXALINE-2-OL;3-AMinoquinoxalin-2-ol;3-aMino-1,2-dihydroquinoxalin-2-one;3-Aminoquinoxalin-2(1H)-one;3-amino-2(1H)-quinoxalinone
• CAS NO: 35015-91-9
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16068
• Mol File: 35015-91-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 375.6 °C at 760 mmHg
• Flash Point: 181 °C
• Appearance: /
• Density: 1.49 g/cm³
• CAS DataBase Reference: 3-AMINO-QUINOXALINE-2-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-QUINOXALINE-2-OL(35015-91-9)
• EPA Substance Registry System: 3-AMINO-QUINOXALINE-2-OL(35015-91-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37
• Hazardous Substances Data: 35015-91-9(Hazardous Substances Data)

Usage

General Description

3-Amino-Quinoxaline-2-ol is a chemical compound that falls into the class of quinoxalines, which are heterocyclic compounds composed of a two-ring structure. It is an important organic intermediate used in agrochemical, pharmaceutical, and dyestuff fields. The compound's unique structure - consisting of a benzene ring fused to a pyrazine ring - gives it noteworthy properties, making it a subject of interest in the field of medicinal chemistry. Its amino and hydroxyl groups can interact favorably with certain biological targets, potentially leading to therapeutic benefits. However, the compound may require careful handling due to potential health implications, and it is recommended to gain proper knowledge and techniques before handling it.

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 144167-25-9 α-amino-α-carbethoxy-N-phenylnitrone 
• 15804-19-0 quinoxaline-2,3-dione 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 
• 617-36-7 Ethyl oxamate 
• 35676-70-1 3-chloro-quinoxaline-2(1H)-one 
• 51216-90-1 ethyl 2-thiooxamate 
• 2213-63-0 2,3-dichloroquinoxaline 
• 816-27-3 ethyl 2-ethoxy-2-iminoacetate 
• 6640-47-7 2,3-diaminoquinoxaline 

Downstream Products

• 62758-32-1 3-benzoylamino-1H-quinoxalin-2-one 
• 34117-90-3 2-amino-3-chloroquinoxaline 
• 103264-47-7 3-acetylamino-quinoxalin-2(1H)-one 
• 31595-63-8 3-hydrazineylidene-3,4-dihydroquinoxalin-2(1H)-one 
• 76002-83-0 ethyl 4,5-dihydro-4-oxoimidazo<1,2-a>quinoxaline-2-carboxylate 
• 76325-47-8 4,5-dihydro-4-oxoimidazo-[1,2-a]-quinoxaline-2-carboxylic acid 
• 177944-77-3 3-(hydroxyimino)-1,4-dihydroquinoxaline-2-one 
• 106271-27-6 4-amino-N-(3-oxo-3,4-dihydro-quinoxalin-2-yl)-benzenesulfonamide 
• 61148-29-6 4-Aminotetrazolo<1,5-a>chinoxalin 
• 83566-29-4 3-amino-6-nitroquinoxalin-2(1H)-one 
• 90564-85-5 3-amino-1-methylquinoxalin-2(1H)-one 
• 109729-03-5 2-(2,3-dimethoxy-phenyl)-oxazolo[4,5-b]quinoxaline 
• 855873-37-9 4-nitro-benzenesulfonic acid-(3-oxo-3,4-dihydro-quinoxalin-2-ylamide) 
• 109602-00-8 2-trans-styryl-oxazolo[4,5-b]quinoxaline 

Relevant articles and documents

Applications of ethyl carboethoxyformimidate to heterocyclic synthesis: Preparation of condensed pyrazinones and 1,4-oxazinones

Aromatic and heteroaromatic 1,2-diamines, and o-aminophenols, condense smoothly with ethyl carboethoxyformimidate to give good yields of condensed pyrazinones and 1,4-oxazinones.

Direct C(sp2)?H Amination to Synthesize Primary 3-aminoquinoxalin-2(1H)-ones under Simple and Mild Conditions

A convenient C?H amination of quinoxalin-2-ones has been developed. This transformation provides concise access to 3-aminoquinoxalin-2(1H)-ones with a broad tolerance of functional groups, utilizing TMSN3 as an amino source under simple and mild conditions. The target 3-aminoquinoxalin-2(1H)-ones are important intermediates for the synthesis of biologically active 3-N-substituted quinoxalin-2-one derivatives. (Figure presented.).

Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives

The reaction of o-phenylene diamine and ethyl oxamate is reinvestigated and led to 3-aminoquinoxalin-2(1H)-one rather than benzimidazole-2-carboxamide as was previously reported. The structure of the obtained quinoxaline has been confirmed by X-ray. The anti-tumor activity of synthesized quinoxalines 1-21 has been evaluated by studying their possible inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13- acetate (TPA). Among the studied compounds 1-21, compounds 12, 8, 13, 18, 17 and 19, respectively, demonstrated strong inhibitory effects on the EBV-EA activation without showing any cytotoxicity and their effects being stronger than that of a representative control, oleanolic acid. Furthermore, compound 12 exhibited a remarkable inhibitory effect on skin tumor promotion in an in vivo two-stage mouse skin carcinogenesis test using 7,12-dimethylbenz[a]anthracene (DMBA) as an initiator and TPA as a promoter. The result of the present investigation indicated that compound 12 might be valuable as a potent cancer chemopreventive agent. Moreover, the molecular docking into PTK (PDB: 1t46) has been done for lead optimization of the aforementioned compounds as potential PTK inhibitors.